Dermatophytic Onychomycosis Treatment Market
Dermatophytic onychomycosis, also known as tinea unguium, is a fungal disease of toenails or fingernails that causes ring infection over nails. Trichophyton rubrum and trichophyton mentagrophytes are common strains of fungi responsible for causing dermatophytic onychomycosis. Furthermore, yeasts and non-dermatophyte molds are other agents that spread the infection. Public places such as gym, swimming pool, and others that are infected with disease causing fungal agents are major source, which cause dermatophytic onychomycosis. Moreover, continuous use of shoes for a longer duration and contact of toe nail with wet surface causes the fungal infection. Increasing incidences of the infection are evident in sportsperson, owing to continuous use of shoe, sweating at nails, and traumatic nail injuries.
Major symptoms of dermatophytic onychomycosis include thickening and whitening of nails. Moreover, the nails become brittle and appear white as the infection progresses. People suffering from diabetes, peripheral vascular disease, HIV, immune suppression, obesity, and geriatric population are at increased risk of this common fungal infection. Dermatophytic onychomycosis could be treated with either topical preparations or oral antifungal agents based on the severity of infection. The treatment often lasts for an average period of six months. In recent past, advancement in therapy with the introduction of effective topical and oral products has controlled the rapid spread of dermatophytic onychomycosis.
The global dermatophytic onychomycosis treatment market size was valued at US$ 2,596.8 million in 2017, and is expected to witness a CAGR of 12.6% over the forecast period (2018 – 2026).
Figure 1. Global Dermatophytic Onychomycosis Treatment Market Value (US$ Mn), by Region, 2017
Source – Coherent Market Insights Report
Increased global prevalence of dermatophytic onychomycosis is expected to propel growth of the dermatophytic onychomycosis treatment market
Dermatophytic onychomycosis is most common nail disorder. According to a report in the Journal of Cutaneous Medicine and Surgery, 2017, onychomycosis accounts for 50% of all nail diseases and prevalence of onychomycosis was estimated to be 5.5% with margin of error of + 3% worldwide. Prophylactic use of topical antifungal agent is expected to aid in effective treatment of dermatophytic onychomycosis, which in turn is major factor contributing to the market growth.
However, several factors deter growth for the dermatophytic onychomycosis treatment market. For instance, treatment of dermatophytic onychomycosis on an average lasts for 5-6 months and with such long term course, patient’s compliance is a critical problem with dose fatigue and adverse effects on body parts such as liver, kidney, and heart (hepatic, renal impairment).
Moreover, high risk of disease recurrence negatively impacts the dermatophytic onychomycosis treatment market growth due to unwillingness of patients to follow treatment that lasts long. Furthermore, several patients often neglect this fungal infection which results in large number of population devoid of therapy access, which in turn hampers the market growth.
Figure 2. Global Dermatophytic Onychomycosis Treatment Market Share, By Therapy Type
Source – Coherent Market Insights Report
Development of new therapies that aid in treatment of dermatophytic onychomycosis is expected to drive growth of the dermatophytic onychomycosis treatment market over the forecast period
Introduction of new drug candidates and adoption of new treatment approaches is a major factor contributing to the dermatophytic onychomycosis treatment market growth. For instance, in 2014, the U.S. Food and Drug Administration (FDA) approved two new topical antifungal drugs—efinaconazole and tavaborole— for the treatment of dermatophytic onychomycosis caused by Trichophyton rubrum and Trichophyton mentagrophytes. Efinaconazole is the first approved topical triazole antifungal agent and tavaborole is the first approved oxobarole antifungal agent for this indication. These agents offer short treatment courses, high cure rates, and few relapse cases.
Moreover, increasing preference of laser-based therapy for external treatment of dermatophytic onychomycosis is expected to propel the market growth. The treatment is preferred by patients with drug adversity aroused from continuous use of systemic antifungal agents. Furthermore, Ionophresis and photodynamic therapy which are emerging approaches to treat dermatophytic onychomycosis are witnessing significant growth, owing to efforts going on establishing clinical evidence for them.
Key players operating in the dermatophytic onychomycosis treatment market include, Bausch Health Companies, Galderma S.A., Celtic Pharma, Anacor pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., GlaxoSmithKline, Topica Pharmaceuticals, Inc., Moberg Pharma AB, Bayer AG, Dr. Reddy’s Laboratories Ltd, Allergen, Inc., Cipla Ltd, Medimetriks Pharmaceuticals Inc., Sanofi S.A., NovaBiotics Inc., and Merz Pharma.
Nail onychomycosis or fungus infection is caused by a fungus called Trichophyton rubrum and Trichophyton mentagrophytes. However, few cases may also be caused by yeasts and molds. Fungi grow and spread due to conditions of warmth and moisture. The infection begins as a white or yellow spot under the tip of the nail and as it spreads deeper into the nail, it causes potentially painful nail discoloration, thickening, and development of crumbling edges. Onychomycosis commonly affects toenails than in fingernails, as toenails are often confined in a dark, warm, moist environment inside shoes where fungi can thrive. Old age people are more likely to be affected by the disease due to suppressed nail growth and immunity, and other complications.
Major driver for growth of the dermatophytic onychomycosis treatment market is high prevalence of dermatophytic onychomycosis worldwide. According to a study published in the Journal of the European Academy of Dermatology and Venereology in 2013, the mean prevalence of dermatophytic onychomycosis in Europe and North America was 4.3% in the population-based studies and 8.9% in the hospital-based studies. According to the Centre for Disease Control and Prevention statistics in 2017, around 23 million people in the U.S. are affected by this disease each year.
Increasing geriatric population across the globe is another major factor driving growth of the market. According to the Population Prospects report by the United Nations, the number of people aged 60 years and above would reach 1.3 billion by 2025.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 19 market data tables and 23 figures on “Dermatophytic Onychomycosis Treatment Market” - Global forecast to 2026”.
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.